Emma Osterholzer, PA
Physician Assistant · Saginaw, MINPI 1942875893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 787 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,332, more than ten times the $241 reported in 2021. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 787 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$2K
- Sanofi$1K
- Johnson & Johnson$1K
- Incyte Corporation$1K
- Novartis$933
- plus $6K from 28 others
What the payments were for
- Food & beverage$12,81091%
- Education$1,2839%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $2,495 |
| Sun Pharmaceutical Industries Inc. | 79 | $1,504 |
| Sanofi | 56 | $1,147 |
| Johnson & Johnson | 26 | $1,109 |
| Incyte Corporation | 76 | $1,047 |
| Novartis | 80 | $933 |
| E.r. Squibb & Sons, L.L.C. | 49 | $710 |
| Amgen | 29 | $617 |
| UCB, Inc. | 28 | $613 |
| Regeneron Healthcare Solutions, Inc. | 25 | $603 |
| LEO Pharma Inc. | 31 | $451 |
| Lilly USA, LLC | 20 | $398 |
| Pfizer | 26 | $394 |
| Galderma Laboratories, L.p. | 30 | $296 |
| Dermavant Sciences, Inc. | 11 | $252 |
| Arcutis Biotherapeutics, Inc. | 11 | $243 |
| Boehringer Ingelheim | 6 | $162 |
| Sanofi-aventis U.S. LLC | 2 | $160 |
| Janssen Scientific Affairs, LLC | 2 | $156 |
| Mayne Pharma Commercial LLC | 13 | $148 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $116 |
| Organon | 5 | $93 |
| Journey Medical Corporation | 4 | $74 |
| Smith+Nephew | 3 | $72 |
| Verrica Pharmaceuticals Inc. | 4 | $72 |
| Organogenesis Inc. | 3 | $65 |
| Convatec Inc. | 1 | $29 |
| Almirall LLC | 1 | $23 |
| Mimedx Group, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Botanix SB Inc | 1 | $20 |
| LNHC, Inc | 1 | $20 |
| Kerecis Limited | 1 | $15 |
| Strata Skin Sciences, Inc. | 1 | $15 |
How this compares
$14,093 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 31 | $648,818 |
| Dupixent PenDupilumab | 108 | $398,963 |
| Cosentyx Unoready PenSecukinumab | 15 | $131,854 |
| Taltz AutoinjectorIxekizumab | 12 | $81,658 |
| Humira(Cf) PenAdalimumab | 12 | $73,468 |
| OpzeluraRuxolitinib Phosphate | 13 | $25,093 |
| Pimecrolimus | 14 | $6,207 |
| Clobetasol Propionate | 125 | $4,339 |
| Ketoconazole | 172 | $3,496 |
| Triamcinolone Acetonide | 221 | $2,007 |
| Metronidazole | 56 | $1,995 |
| Fluorouracil | 26 | $1,842 |
| Tacrolimus | 11 | $1,790 |
| Betamethasone Dipropionate | 49 | $1,647 |
| Ammonium Lactate | 73 | $1,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $1,047 | $25,09313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Saginaw
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.